DCAT Value Chain Insights

CDMO/CMO Watch: Cambrex, The Next End-to-End Provider in the Offing

Cambrex, a contract manufacture of small-molecule active pharmaceutical ingredients, is the latest contract manufacturer to establish an end-to-end-business model with its pending $425-million...

Emerging Pharma: Who is Rising to the Top?

Emerging pharma companies are an important source of product innovation for the pharmaceutical industry, so which companies are making the mark? DCAT Value Chain Insights takes an inside look. For...

Drug Pricing: What is Brewing in Policy Debates?
Taking Supplier Relationship Management to the Next Level
What's Next for Pfizer?
Brexit: Are Pharma Companies Prepared?

Mid-Year Review: New Drug Approvals Stay on Track
Mid-Year Review: The Top 10 Deals of 2018
CDMO Outlook: Preparing for the Next Opportunity
Read more...

Top Industry News

Perrigo To Separate Prescription Drug Business

Mylan Forms Strategic Review Committee to Evaluate Options for its Businesses

FDA OKs First Generic Under Pathway to Aid Competition for Sole-Source Drugs

White House Proposes Cuts in US Opioid Production

Emergent BioSolutions To Acquire Specialty Vaccines Company PaxVax

More DCAT Value Chain Insights Feature Articles

Top Industry News

Login Form